

HIV-1 neutralizing antibodies induced by native-like en

Science

349, aac4223

DOI: [10.1126/science.aac4223](https://doi.org/10.1126/science.aac4223)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The <scp>HIV</scp> glycan shield as a target for broadly neutralizing antibodies. FEBS Journal, 2015, 282, 4679-4691.	2.2	106
2	Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology, 2015, 12, 82.	0.9	156
3	Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. Biomolecules, 2015, 5, 2919-2934.	1.8	12
4	Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. Journal of Immunology Research, 2015, 2015, 1-17.	0.9	66
5	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell, 2015, 163, 1702-1715.	13.5	341
6	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathogens, 2015, 11, e1004932.	2.1	141
7	Toward an HIV vaccine: A scientific journey. Science, 2015, 349, 386-387.	6.0	22
8	The modern era of HIV-1 vaccine development. Science, 2015, 349, 139-140.	6.0	36
9	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nature Structural and Molecular Biology, 2015, 22, 522-531.	3.6	333
10	Tailored immunogens for rationally designed antibody-based HIV-1 vaccines. Trends in Immunology, 2015, 36, 437-439.	2.9	8
11	Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine, 2015, 7, 310rv7.	5.8	179
12	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of Virology, 2015, 89, 10383-10398.	1.5	148
13	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. Journal of Virology, 2015, 89, 12501-12512.	1.5	83
14	Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11947-11952.	3.3	127
15	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of Virology, 2015, 89, 12189-12210.	1.5	88
16	Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology, 2015, 486, 116-120.	1.1	42
17	Recent update in HIV vaccine development. Clinical and Experimental Vaccine Research, 2016, 5, 6.	1.1	26
18	AIDS Vaccines. , 2016, , 401-422.		1

#	ARTICLE	IF	CITATIONS
19	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. <i>PLoS Pathogens</i> , 2016, 12, e1005815.	2.1	104
20	Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. <i>PLoS Pathogens</i> , 2016, 12, e1005989.	2.1	36
21	Which Vaccination Strategies and Immune Responses are More Effective Against HIV Infections?. , 0, , .		0
22	An HIV Vaccine. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 143.	3.8	24
23	Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. <i>Nature Communications</i> , 2016, 7, 12040.	5.8	134
24	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. <i>Nature Communications</i> , 2016, 7, 12041.	5.8	146
25	First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. <i>Retrovirology</i> , 2016, 13, 82.	0.9	21
26	Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies. <i>Aids</i> , 2016, 30, 2179-2184.	1.0	3
27	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. <i>Biochemistry</i> , 2016, 55, 2197-2213.	1.2	23
28	Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. <i>Journal of Experimental Medicine</i> , 2016, 213, 469-481.	4.2	299
29	Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers. <i>Journal of Virology</i> , 2016, 90, 2806-2817.	1.5	126
30	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. <i>Journal of Infectious Diseases</i> , 2016, 213, 1946-1954.	1.9	14
31	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. <i>Journal of Immunology</i> , 2016, 196, 3064-3078.	0.4	56
32	A shot at AIDS. <i>Current Opinion in Biotechnology</i> , 2016, 42, 147-151.	3.3	9
33	Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen. <i>ACS Chemical Biology</i> , 2016, 11, 1702-1709.	1.6	9
34	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016, 165, 813-826.	13.5	379
35	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. <i>Annual Review of Immunology</i> , 2016, 34, 635-659.	9.5	500
36	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. <i>Science</i> , 2016, 353, 1557-1560.	6.0	147

#	ARTICLE	IF	CITATIONS
37	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016, 166, 1459-1470.e11.	13.5	230
38	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. <i>Cell</i> , 2016, 166, 1445-1458.e12.	13.5	270
39	High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. <i>Cell Reports</i> , 2016, 15, 1986-1999.	2.9	127
40	Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. <i>Vaccine</i> , 2016, 34, 5344-5351.	1.7	11
41	Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6639-E6648.	3.3	286
42	HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. <i>Journal of Virology</i> , 2016, 90, 10587-10599.	1.5	18
43	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	6.6	335
44	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. <i>Journal of Virology</i> , 2016, 90, 9224-9236.	1.5	25
45	A shared N-terminal hydrophobic tail for the formation of nanoparticulates. <i>Nanomedicine</i> , 2016, 11, 2289-2303.	1.7	5
46	Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates. <i>Journal of Virology</i> , 2016, 90, 9471-9482.	1.5	43
47	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	1.5	13
48	Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2016, 90, 8842-8854.	1.5	34
49	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016, 16, 2327-2338.	2.9	216
50	Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. <i>Cell Reports</i> , 2016, 17, 2195-2209.	2.9	150
51	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16068.	1.8	48
52	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. <i>Retrovirology</i> , 2016, 13, 48.	0.9	20
53	Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice. <i>Vaccine</i> , 2016, 34, 6276-6284.	1.7	4
54	Elimination of HIV-1-infected cells by broadly neutralizing antibodies. <i>Nature Communications</i> , 2016, 7, 10844.	5.8	201

#	ARTICLE	IF	CITATIONS
55	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	5.8	86
56	Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. <i>Science Immunology</i> , 2016, 1, aag0851.	5.6	120
57	An HIV-1 Env Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. <i>Journal of Immunology</i> , 2016, 197, 3982-3998.	0.4	17
58	Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. <i>Cell Reports</i> , 2016, 17, 1560-1570.	2.9	42
59	Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. <i>Scientific Reports</i> , 2016, 6, 34108.	1.6	106
60	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	2.7	34
61	Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. <i>Retrovirology</i> , 2016, 13, 81.	0.9	10
62	Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. <i>Aids</i> , 2016, 30, 2405-2414.	1.0	14
63	Approaches to the induction of HIV broadly neutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 569-575.	1.5	15
64	Novel approaches in preclinical HIV vaccine research. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 601-606.	1.5	2
65	Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities. <i>ChemMedChem</i> , 2016, 11, 357-362.	1.6	11
66	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. <i>Journal of Virology</i> , 2016, 90, 813-828.	1.5	34
67	HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant. <i>Cell</i> , 2016, 166, 77-87.	13.5	143
68	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
69	Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2640-2648.	1.4	36
70	Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. <i>Journal of Immunology</i> , 2016, 197, 994-1002.	0.4	130
71	B cells in HIV pathogenesis. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 23-30.	1.3	10
72	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. <i>Expert Review of Vaccines</i> , 2016, 15, 349-365.	2.0	44

#	ARTICLE	IF	CITATIONS
73	Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. <i>Journal of Virology</i> , 2016, 90, 1682-1686.	1.5	10
74	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. <i>Expert Review of Vaccines</i> , 2016, 15, 719-729.	2.0	30
75	Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. <i>Science</i> , 2016, 351, 1043-1048.	6.0	402
76	High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. <i>Journal of Immunology</i> , 2016, 196, 3729-3743.	0.4	26
77	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. <i>Trends in Immunology</i> , 2016, 37, 221-232.	2.9	96
78	CXCL13 is a plasma biomarker of germinal center activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2702-2707.	3.3	322
79	Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. <i>Journal of Virology</i> , 2016, 90, 4481-4493.	1.5	13
80	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016, 19, 292-303.	5.1	143
81	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. <i>Cell Reports</i> , 2016, 14, 2695-2706.	2.9	250
82	New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. <i>Expert Review of Vaccines</i> , 2016, 15, 1015-1027.	2.0	9
83	Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIV SF162P3N-Infected Macaques. <i>Journal of Virology</i> , 2016, 90, 4017-4031.	1.5	24
84	Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins. <i>Journal of Virology</i> , 2016, 90, 2884-2894.	1.5	28
85	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , 2016, 90, 2740-2755.	1.5	58
86	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	3.6	162
87	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	2.9	45
88	An overview of the lagomorph immune system and its genetic diversity. <i>Immunogenetics</i> , 2016, 68, 83-107.	1.2	32
89	Current views on the potential for development of a HIV vaccine. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 295-303.	1.4	23
90	Native-like Env trimers as a platform for HIV vaccine design. <i>Immunological Reviews</i> , 2017, 275, 161-182.	2.8	221

#	ARTICLE	IF	CITATIONS
91	Identification and specificity of broadly neutralizing antibodies against <scp>HIV</scp>. Immunological Reviews, 2017, 275, 11-20.	2.8	198
92	Evolution of B cell analysis and Env trimer redesign. Immunological Reviews, 2017, 275, 183-202.	2.8	31
93	Immunologic characteristics of <scp>HIV</scp>-infected individuals who make broadly neutralizing antibodies. Immunological Reviews, 2017, 275, 62-78.	2.8	58
94	The <scp>HIV</scp>-1 envelope glycoprotein structure: nailing down a moving target. Immunological Reviews, 2017, 275, 21-32.	2.8	251
95	Tfh cells and <scp>HIV</scp> bnAbs, an immunodominance model of the <scp>HIV</scp> neutralizing antibody generation problem. Immunological Reviews, 2017, 275, 49-61.	2.8	167
96	Ontogeny-based immunogens for the induction of V2-directed <scp>HIV</scp> broadly neutralizing antibodies. Immunological Reviews, 2017, 275, 217-229.	2.8	27
97	Human Ig knockin mice to study the development and regulation of <scp>HIV</scp>-1 broadly neutralizing antibodies. Immunological Reviews, 2017, 275, 89-107.	2.8	37
98	Germinal Center Lymphocyte Ratios and Successful HIV Vaccines. Trends in Molecular Medicine, 2017, 23, 95-97.	3.5	6
99	Vaccine nanoparticles for protection against HIV infection. Nanomedicine, 2017, 12, 673-682.	1.7	22
100	Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. MBio, 2017, 8, .	1.8	28
101	Progress in HIV vaccine development. Human Vaccines and Immunotherapeutics, 2017, 13, 1018-1030.	1.4	80
102	Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer. Journal of Virology, 2017, 91, .	1.5	19
103	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	2.9	69
104	Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Current Opinion in HIV and AIDS, 2017, 12, 241-249.	1.5	43
105	Particle-based delivery of the HIV envelope protein. Current Opinion in HIV and AIDS, 2017, 12, 265-271.	1.5	16
106	The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans. Structure, 2017, 25, 773-782.e5.	1.6	39
107	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. Virology, 2017, 507, 242-256.	1.1	5
108	Guiding the long way to broad HIV neutralization. Current Opinion in HIV and AIDS, 2017, 12, 257-264.	1.5	15

#	ARTICLE	IF	CITATIONS
109	Dense Array of Spikes on HIV-1 Virion Particles. <i>Journal of Virology</i> , 2017, 91, .	1.5	53
110	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	2.9	160
111	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
112	Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	71
113	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. <i>Journal of Virology</i> , 2017, 91, .	1.5	57
114	Adjuvants. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 278-284.	1.5	27
115	How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 229-240.	1.5	66
116	Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. <i>Journal of Virology</i> , 2017, 91, .	1.5	27
117	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. <i>Nature Communications</i> , 2017, 8, 14954.	5.8	176
118	Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. <i>Virology</i> , 2017, 505, 193-209.	1.1	36
119	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
120	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	0.5	18
121	Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
122	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. <i>Cell Reports</i> , 2017, 21, 222-235.	2.9	58
123	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. <i>Cell Reports</i> , 2017, 20, 1805-1817.	2.9	171
124	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
125	Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. <i>Expert Review of Vaccines</i> , 2017, 16, 973-985.	2.0	27
126	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017, 214, 2573-2590.	4.2	151



#	ARTICLE	IF	CITATIONS
127	High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. <i>Journal of Virology</i> , 2017, 91, .	1.5	22
128	Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. <i>Immunity</i> , 2017, 47, 524-537.e3.	6.6	48
129	Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. <i>Scientific Reports</i> , 2017, 7, 8390.	1.6	31
130	Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. <i>Nature</i> , 2017, 548, 108-111.	13.7	154
131	Breaching peripheral tolerance promotes the production of HIV-1 neutralizing antibodies. <i>Journal of Experimental Medicine</i> , 2017, 214, 2283-2302.	4.2	50
132	Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. <i>Journal of Biological Chemistry</i> , 2017, 292, 15849-15858.	1.6	12
133	Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins. <i>MAbs</i> , 2017, 9, 1052-1064.	2.6	7
134	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. <i>Cell Reports</i> , 2017, 21, 2992-3002.	2.9	69
135	Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. <i>Nature Communications</i> , 2017, 8, 1655.	5.8	142
136	Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus. <i>Annual Review of Virology</i> , 2017, 4, 491-510.	3.0	2
137	Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. <i>Virology</i> , 2017, 510, 22-28.	1.1	11
138	Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. <i>Nature</i> , 2017, 547, 360-363.	13.7	217
139	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. <i>Nature Microbiology</i> , 2017, 2, 16199.	5.9	144
140	A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells. <i>Journal of Virology</i> , 2017, 91, .	1.5	28
141	Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. <i>Journal of Virology</i> , 2017, 91, .	1.5	77
142	Structure of the transmembrane domain of HIV-1 envelope glycoprotein. <i>FEBS Journal</i> , 2017, 284, 1171-1177.	2.2	18
143	Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2017, 292, 278-291.	1.6	18
144	Natural infection as a blueprint for rational HIV vaccine design. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 229-236.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	2.9	97
146	ISCOMATRIX Adjuvant in the Development of Prophylactic and Therapeutic Vaccines. , 2017, , 311-332.		5
147	Broadly Neutralizing Antibodies. , 2017, , 3-21.		2
148	Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus. <i>Viruses</i> , 2017, 9, 148.	1.5	52
149	Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in Mice. <i>Frontiers in Immunology</i> , 2017, 8, 1654.	2.2	9
150	Humanized Immunoglobulin Mice. <i>Advances in Immunology</i> , 2017, 134, 235-352.	1.1	14
151	A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006178.	2.1	69
152	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	5.8	76
153	Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines. <i>AIDS Research and Therapy</i> , 2017, 14, 47.	0.7	9
154	Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers <i>In Vitro</i>. <i>Journal of Virology</i> , 2018, 92, .	1.5	34
155	Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , 2018, 92, .	1.5	40
156	Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11. <i>Journal of Virology</i> , 2018, 92, .	1.5	16
157	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
158	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. <i>Journal of Proteome Research</i> , 2018, 17, 987-999.	1.8	23
159	Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 365-374.	0.5	8
160	Neutralization tiers of HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 128-136.	1.5	89
161	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	30
162	Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection. <i>Aids</i> , 2018, 32, 555-563.	1.0	17

#	ARTICLE	IF	CITATIONS
163	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
164	Nanoparticle vaccines against viral infections. <i>Archives of Virology</i> , 2018, 163, 2313-2325.	0.9	36
165	Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. <i>Journal of Virology</i> , 2018, 92, .	1.5	66
166	Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. <i>Virus Research</i> , 2018, 243, 75-82.	1.1	12
167	Cross-reactivity of HIV vaccine responses and the microbiome. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 9-14.	1.5	31
168	Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. <i>Virology</i> , 2018, 514, 106-117.	1.1	29
169	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2018, 293, 1688-1701.	1.6	40
170	EDiP: the Epitope Dilution Phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens. <i>Expert Review of Vaccines</i> , 2018, 17, 13-21.	2.0	5
171	Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. <i>Journal of Biological Chemistry</i> , 2018, 293, 830-846.	1.6	11
172	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. <i>Biotechnology and Bioengineering</i> , 2018, 115, 885-899.	1.7	75
173	Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions. <i>Journal of Virology</i> , 2018, 92, .	1.5	8
174	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. <i>PLoS ONE</i> , 2018, 13, e0208345.	1.1	8
175	Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. <i>Scientific Reports</i> , 2018, 8, 16527.	1.6	69
176	Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India. <i>Frontiers in Immunology</i> , 2018, 9, 2841.	2.2	4
177	HIV-1 vaccine design through minimizing envelope metastability. <i>Science Advances</i> , 2018, 4, eaau6769.	4.7	75
178	Divergent Primary Immune Responses Induced by Human Immunodeficiency Virus-1 gp120 and Hepatitis B Surface Antigen Determine Antibody Recall Responses. <i>Virologica Sinica</i> , 2018, 33, 502-514.	1.2	2
179	HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. <i>Retrovirology</i> , 2018, 15, 74.	0.9	26
180	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. <i>Cell Host and Microbe</i> , 2018, 24, 593-599.e3.	5.1	24

#	ARTICLE	IF	CITATIONS
181	B Cell Competition for Restricted T Cell Help Suppresses Rare-Epitope Responses. <i>Cell Reports</i> , 2018, 25, 321-327.e3.	2.9	42
182	Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10116-10125.	2.9	21
183	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. <i>Cell Reports</i> , 2018, 25, 893-908.e7.	2.9	91
184	Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys. <i>Frontiers in Immunology</i> , 2018, 9, 2415.	2.2	19
185	Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	3.0	7
186	Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. <i>Retrovirology</i> , 2018, 15, 63.	0.9	34
187	The Neutralizing Antibody Response to the HIV-1 Env Protein. <i>Current HIV Research</i> , 2018, 16, 21-28.	0.2	24
188	Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. <i>Nature Communications</i> , 2018, 9, 1956.	5.8	50
189	The wide utility of rabbits as models of human diseases. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-10.	3.2	103
190	Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies. <i>Scientific Reports</i> , 2018, 8, 7807.	1.6	8
191	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	4.2	29
192	Strategies for a multi-stage neutralizing antibody-based HIV vaccine. <i>Current Opinion in Immunology</i> , 2018, 53, 143-151.	2.4	105
194	Mapping mutational effects along the evolutionary landscape of HIV envelope. <i>ELife</i> , 2018, 7, .	2.8	96
195	B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques. <i>PLoS Pathogens</i> , 2018, 14, e1007120.	2.1	4
196	Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail. <i>Retrovirology</i> , 2018, 15, 50.	0.9	15
197	Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?. <i>Retrovirology</i> , 2018, 15, 52.	0.9	29
198	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986.	2.1	28
199	DEER Spectroscopy Measurements Reveal Multiple Conformations of HIV-1 SOSIP Envelopes that Show Similarities with Envelopes on Native Virions. <i>Immunity</i> , 2018, 49, 235-246.e4.	6.6	68

#	ARTICLE	IF	CITATIONS
200	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. <i>Immunity</i> , 2018, 49, 288-300.e8.	6.6	175
201	Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice. <i>PLoS ONE</i> , 2018, 13, e0193680.	1.1	23
202	Targeting Glycans on Human Pathogens for Vaccine Design. <i>Current Topics in Microbiology and Immunology</i> , 2018, 428, 129-163.	0.7	5
203	Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 1116.	2.2	27
204	HIV Vaccination: A Roadmap among Advancements and Concerns. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1241.	1.8	34
205	The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. <i>Viruses</i> , 2018, 10, 197.	1.5	18
206	Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 760-768.	0.5	2
207	Immune Correlate-Guided HIV Vaccine Design. <i>Cell Host and Microbe</i> , 2018, 24, 25-33.	5.1	44
208	Virus-Like-Vaccines against HIV. <i>Vaccines</i> , 2018, 6, 10.	2.1	19
209	Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. <i>Science Immunology</i> , 2018, 3, .	5.6	78
210	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. <i>PLoS Computational Biology</i> , 2018, 14, e1006093.	1.5	19
211	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007238.	2.1	18
212	Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. <i>Cell Reports</i> , 2018, 24, 1958-1966.e5.	2.9	120
213	One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice. <i>EMBO Journal</i> , 2018, 37, .	3.5	28
214	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	15.2	256
215	Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. <i>Cell Reports</i> , 2018, 23, 3249-3261.	2.9	52
216	Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. <i>Cell Host and Microbe</i> , 2018, 23, 832-844.e6.	5.1	43
217	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. <i>PLoS Pathogens</i> , 2018, 14, e1006913.	2.1	111

#	ARTICLE	IF	CITATIONS
218	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
219	Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16473-16478.	3.3	141
220	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS Pathogens, 2019, 15, e1007920.	2.1	61
221	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. Cell, 2019, 178, 567-584.e19.	13.5	106
222	Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. Vaccines, 2019, 7, 76.	2.1	40
223	Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins. Journal of Virology, 2019, 93, .	1.5	18
224	Stoichiometric Analyses of Soluble CD4 to Native-like HIV-1 Envelope by Single-Molecule Fluorescence Spectroscopy. Cell Reports, 2019, 29, 176-186.e4.	2.9	11
225	Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. Vaccines, 2019, 7, 119.	2.1	5
226	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature Communications, 2019, 10, 4272.	5.8	149
227	New Vaccine Design and Delivery Technologies. Journal of Infectious Diseases, 2019, 219, S88-S96.	1.9	53
228	Follicular T-cell subsets in HIV infection. Current Opinion in HIV and AIDS, 2019, 14, 71-76.	1.5	10
229	Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. Frontiers in Immunology, 2019, 10, 1021.	2.2	8
230	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. PLoS Biology, 2019, 17, e3000328.	2.6	33
231	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	5.8	116
232	HIV-1-Based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions. Viruses, 2019, 11, 507.	1.5	17
233	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell Host and Microbe, 2019, 25, 873-883.e5.	5.1	42
234	Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor. Molecules, 2019, 24, 1581.	1.7	8
235	Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. Cell, 2019, 177, 1153-1171.e28.	13.5	293

#	ARTICLE	IF	CITATIONS
236	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. <i>Cell Reports</i> , 2019, 27, 2426-2441.e6.	2.9	35
237	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	1.1	41
238	Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens. <i>PLoS ONE</i> , 2019, 14, e0213409.	1.1	5
239	Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines. <i>Current Opinion in Immunology</i> , 2019, 59, 49-56.	2.4	24
240	Protein and Glycan Mimicry in HIV Vaccine Design. <i>Journal of Molecular Biology</i> , 2019, 431, 2223-2247.	2.0	91
241	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. <i>Nature Microbiology</i> , 2019, 4, 734-747.	5.9	158
242	The Antibodiome—Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 169-179.	1.1	13
243	Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2264-2277.	1.6	16
244	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2019, 294, 5616-5631.	1.6	16
245	The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent Neutralization Epitope following Immunization. <i>Cell Reports</i> , 2019, 27, 586-598.e6.	2.9	32
246	Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
247	Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. <i>Viruses</i> , 2019, 11, 159.	1.5	13
248	Determination of neutralization activities by a new versatile assay using an HIV-1 genome carrying the <i>Gussia luciferase</i> gene. <i>Journal of Virological Methods</i> , 2019, 267, 22-28.	1.0	4
249	Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities. <i>ACS Central Science</i> , 2019, 5, 237-249.	5.3	33
250	Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. <i>Nature Communications</i> , 2019, 10, 763.	5.8	30
251	Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies. <i>Nature Communications</i> , 2019, 10, 948.	5.8	19
252	A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses. <i>Viruses</i> , 2019, 11, 160.	1.5	12
253	Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. <i>Journal of Virology</i> , 2019, 93, .	1.5	32

#	ARTICLE	IF	CITATIONS
254	SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. <i>Journal of Virology</i> , 2019, 94, .	1.5	4
255	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. <i>Immunity</i> , 2019, 51, 915-929.e7.	6.6	111
256	Strategies for inducing effective neutralizing antibody responses against HIV-1. <i>Expert Review of Vaccines</i> , 2019, 18, 1127-1143.	2.0	23
257	Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 302-308.	1.5	27
258	Correlates of broadly neutralizing antibody development. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 279-285.	1.5	9
259	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 2793.	2.2	2
260	Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 16, 206-216.	1.7	22
261	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
262	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
263	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	5.1	124
264	Accelerating HIV vaccine development using non-human primate models. <i>Expert Review of Vaccines</i> , 2019, 18, 61-73.	2.0	16
265	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. <i>Journal of Virology</i> , 2019, 93, .	1.5	66
266	Can we use structural knowledge to design a protective vaccine against HIV-1? <i>Hla</i> , 2020, 95, 95-103.	0.4	5
267	Presentation of HIV-1 Envelope Trimers on the Surface of Silica Nanoparticles. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 911-921.	1.6	19
268	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	23
269	Broadly neutralizing antibodies and vaccine design against HIV-1 infection. <i>Frontiers of Medicine</i> , 2020, 14, 30-42.	1.5	24
270	Critical design criteria for engineering a nanoparticulate HIV-1 vaccine. <i>Journal of Controlled Release</i> , 2020, 317, 322-335.	4.8	19
271	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. <i>Journal of Virology</i> , 2020, 94, .	1.5	11



#	ARTICLE	IF	CITATIONS
272	Engineering Antiviral Vaccines. ACS Nano, 2020, 14, 12370-12389.	7.3	50
273	Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. Cell Reports, 2020, 32, 108122.	2.9	28
274	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. Journal of Virology, 2020, 95, .	1.5	5
275	DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens. Vaccine, 2020, 38, 7445-7454.	1.7	0
276	Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design. Current Topics in Microbiology and Immunology, 2020, 428, 31-87.	0.7	0
277	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Npj Vaccines, 2020, 5, 107.	2.9	11
278	Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Frontiers in Immunology, 2020, 11, 590780.	2.2	72
279	Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non-“Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae. Journal of Immunology, 2020, 204, 903-913.	0.4	8
280	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS Pathogens, 2020, 16, e1008665.	2.1	52
281	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS Pathogens, 2020, 16, e1008753.	2.1	61
282	A Zigzag but Upward Way to Develop an HIV-1 Vaccine. Vaccines, 2020, 8, 511.	2.1	5
283	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerging Microbes and Infections, 2020, 9, 2076-2090.	3.0	53
284	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Journal of Virology, 2020, 94, .	1.5	5
285	Probing the Structure of the HIV-1 Envelope Trimer Using Aspartate Scanning Mutagenesis. Journal of Virology, 2020, 94, .	1.5	4
286	Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines, 2020, 8, 440.	2.1	8
287	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. Npj Vaccines, 2020, 5, 72.	2.9	39
288	Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?. , 2020, 8, 251513552095776.	1.4	4
289	Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. IScience, 2020, 23, 101836.	1.9	11

#	ARTICLE	IF	CITATIONS
290	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
291	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. <i>Nature Medicine</i> , 2020, 26, 932-940.	15.2	124
292	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. <i>Frontiers in Immunology</i> , 2020, 11, 984.	2.2	9
293	Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. <i>Science Advances</i> , 2020, 6, eaba0468.	4.7	31
294	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. <i>Science Advances</i> , 2020, 6, eaba0512.	4.7	18
295	COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	1.5	79
296	One-step sequence and structure-guided optimization of HIV-1 envelope gp140. <i>Current Research in Structural Biology</i> , 2020, 2, 45-55.	1.1	12
297	A Systematic Approach to HIV-1 Vaccine Immunogen Selection. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 762-770.	0.5	6
298	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. <i>Journal of Immunology</i> , 2020, 204, 1543-1561.	0.4	4
299	The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans. <i>ACS Chemical Biology</i> , 2020, 15, 789-798.	1.6	9
300	Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants. <i>Plant Biotechnology Journal</i> , 2020, 18, 2109-2117.	4.1	47
301	Innovations in HIV-1 Vaccine Design. <i>Clinical Therapeutics</i> , 2020, 42, 499-514.	1.1	20
302	Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles. <i>Vaccines</i> , 2020, 8, 54.	2.1	11
303	Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques. <i>Viruses</i> , 2020, 12, 163.	1.5	6
304	Stabilized diverse HIV-1 envelope trimers for vaccine design. <i>Emerging Microbes and Infections</i> , 2020, 9, 775-786.	3.0	12
305	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
306	Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2020, 94, .	1.5	27
307	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. <i>Vaccines</i> , 2020, 8, 171.	2.1	6

#	ARTICLE	IF	CITATIONS
308	Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. <i>Cell Host and Microbe</i> , 2020, 27, 507-518.	5.1	42
309	Characterization and Immunogenicity of HIV Envelope gp140 Zera <sup>®</sup> Tagged Antigens. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 321.	2.0	4
310	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. <i>Journal of Virology</i> , 2020, 94, .	1.5	29
311	Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines. <i>Vaccine</i> , 2020, 38, 3821-3831.	1.7	10
312	Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions. <i>Journal of Virology</i> , 2021, 95, .	1.5	26
313	Design and characterization of a germ-line targeting soluble, native-like, trimeric HIV-1 Env lacking key glycans from the V1V2-loop. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129733.	1.1	2
314	Nano-based approaches in the development of antiviral agents and vaccines. <i>Life Sciences</i> , 2021, 265, 118761.	2.0	20
315	Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. <i>Journal of Controlled Release</i> , 2021, 330, 529-539.	4.8	31
317	HIV vaccinology: 2021 update. <i>Seminars in Immunology</i> , 2021, 51, 101470.	2.7	31
318	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. <i>Npj Vaccines</i> , 2021, 6, 24.	2.9	33
319	Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	6
320	The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1009257.	2.1	23
322	Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. <i>Frontiers in Immunology</i> , 2021, 12, 623996.	2.2	10
323	Virus vaccines: proteins prefer prolines. <i>Cell Host and Microbe</i> , 2021, 29, 327-333.	5.1	70
324	Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates. <i>Virologica Sinica</i> , 2021, 36, 784-795.	1.2	1
325	Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env. <i>Vaccines</i> , 2021, 9, 239.	2.1	8
326	Adjuvantâ€mediated enhancement of the immune response to HIV vaccines. <i>FEBS Journal</i> , 2022, 289, 3317-3334.	2.2	10
327	Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer. <i>PLoS Pathogens</i> , 2021, 17, e1008977.	2.1	4

#	ARTICLE	IF	CITATIONS
328	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. <i>Cell Reports</i> , 2021, 35, 108933.	2.9	37
329	Nanotoxoids: Biomimetic Nanoparticle Vaccines against Infections. <i>Advanced Therapeutics</i> , 2021, 4, 2100072.	1.6	10
330	A diverse collection of B cells responded to HIV infection in infant BG505. <i>Cell Reports Medicine</i> , 2021, 2, 100314.	3.3	6
331	Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes. <i>Journal of Virology</i> , 2021, 95, e0000521.	1.5	4
332	A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. <i>Vaccine</i> , 2021, 39, 3379-3387.	1.7	13
334	Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort. <i>Aids</i> , 2021, Publish Ahead of Print, 2073-2084.	1.0	0
335	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	2.1	2
336	Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. <i>Vaccines</i> , 2021, 9, 642.	2.1	9
337	Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. <i>MBio</i> , 2021, 12, e0042921.	1.8	6
338	Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. <i>Science Advances</i> , 2021, 7, .	4.7	37
340	Identification of N-glycans with GalNAc-containing antennae from recombinant HIV trimers by ion mobility and negative ion fragmentation. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 7229-7240.	1.9	1
341	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2021, 6, 103.	2.9	8
342	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. <i>Cell Reports</i> , 2021, 36, 109561.	2.9	9
344	Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. <i>Journal of Virology</i> , 2021, 95, e0009421.	1.5	5
345	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009736.	2.1	18
346	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. <i>Nature Communications</i> , 2021, 12, 4817.	5.8	35
347	Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface. <i>Journal of Virology</i> , 2021, 95, e0053221.	1.5	0
349	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. <i>Vaccines</i> , 2021, 9, 1001.	2.1	2

#	ARTICLE	IF	CITATIONS
350	Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems. <i>Chemical Reviews</i> , 2022, 122, 7562-7623.	23.0	109
352	High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. <i>ELife</i> , 2021, 10, .	2.8	15
353	The Conformational States of the HIV-1 Envelope Glycoproteins. <i>Trends in Microbiology</i> , 2020, 28, 655-667.	3.5	66
354	Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques. <i>Scientific Reports</i> , 2020, 10, 22077.	1.6	7
355	Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. <i>Chemical Biology</i> , 2017, , 300-357.	0.1	4
356	DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. <i>Journal of General Virology</i> , 2017, 98, 2143-2155.	1.3	9
357	Characterization of the membrane-bound form of the chimeric, B/C recombinant HIV-1 Env, LT5.J4b12C. <i>Journal of General Virology</i> , 2018, 99, 1438-1443.	1.3	5
367	Harnessing the protective potential of HIV-1 neutralizing antibodies. <i>F1000Research</i> , 2016, 5, 20.	0.8	4
368	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. <i>PLoS ONE</i> , 2017, 12, e0181886.	1.1	16
369	Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies. <i>PLoS Pathogens</i> , 2016, 12, e1005767.	2.1	72
370	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. <i>PLoS Pathogens</i> , 2016, 12, e1005864.	2.1	138
371	Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. <i>PLoS Pathogens</i> , 2018, 14, e1006825.	2.1	11
372	Taming the AIDS Epidemic: a Commentary on Vaccine and Non-Vaccine Approaches to Combatting HIV-1. , 2016, 2, .		0
373	Antibody Responses and Functions in Defense against Viral Infection. , 2016, , 279-285.		1
382	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. <i>PLoS Pathogens</i> , 2021, 17, e1009807.	2.1	13
383	SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41. <i>Journal of Virology</i> , 2022, 96, JVI0158221.	1.5	0
389	Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25797.	1.2	24
390	Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. <i>Journal of the International AIDS Society</i> , 2021, 24, e25831.	1.2	19

#	ARTICLE	IF	CITATIONS
391	A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. <i>Science Immunology</i> , 2021, 6, eabf1152.	5.6	63
392	Protein engineering strategies for rational immunogen design. <i>Npj Vaccines</i> , 2021, 6, 154.	2.9	26
395	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. <i>Journal of Virology</i> , 2022, 96, JVI0134321.	1.5	10
396	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	1.1	6
397	Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes. <i>Virology</i> , 2022, 568, 41-48.	1.1	9
398	Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. <i>Nature Communications</i> , 2022, 13, 695.	5.8	2
399	Covalent coupling of HIV-1 glycoprotein trimers to biodegradable calcium phosphate nanoparticles via genetically encoded aldehyde-tags. <i>Acta Biomaterialia</i> , 2022, 140, 586-600.	4.1	8
400	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	15.2	80
401	B Cells Discriminate HIV-1 Envelope Protein Affinities by Sensing Antigen Binding Association Rates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
402	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 27.	2.9	13
403	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. <i>Toxins</i> , 2022, 14, 138.	1.5	6
404	Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation. <i>Journal of Virology</i> , 2022, 96, e0166821.	1.5	13
405	Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans. <i>Cell Reports</i> , 2022, 38, 110611.	2.9	3
406	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. <i>Cell Reports</i> , 2022, 38, 110436.	2.9	6
408	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. <i>Advanced Science</i> , 2022, , 2200063.	5.6	3
409	Sendai virus particles carrying target virus glycoproteins for antibody induction. <i>Vaccine</i> , 2022, 40, 2420-2431.	1.7	3
410	mRNA vaccines offer hope for HIV. <i>Nature Medicine</i> , 2021, 27, 2082-2084.	15.2	9
411	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2

#	ARTICLE	IF	CITATIONS
412	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. <i>Structure</i> , 2022, 30, 862-875.e4.	1.6	4
435	Maternal immune protection against infectious diseases. <i>Cell Host and Microbe</i> , 2022, 30, 660-674.	5.1	18
436	Covalent binding of human two-domain CD4 to an HIV-1 subtype C SOSIP.664 trimer modulates its structural dynamics. <i>Biochemical and Biophysical Research Communications</i> , 2022, 612, 181-187.	1.0	0
437	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. <i>Cell Reports Medicine</i> , 2022, 3, 100635.	3.3	3
438	Transchromosomal bovine-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus. <i>Journal of Medical Virology</i> , 2022, 94, 4599-4610.	2.5	6
439	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes. <i>ChemBioChem</i> , 2022, 23, .	1.3	4
440	B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. <i>Cell Reports</i> , 2022, 39, 111021.	2.9	6
442	Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein. <i>Nanotechnology</i> , 2022, 33, 485102.	1.3	5
443	Identification of Highly Potent Transmission-Blocking Human Monoclonal Antibodies to <i>Plasmodium falciparum</i> Pfs230 in Naturally Exposed Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
444	Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques. <i>Cell Reports Medicine</i> , 2022, 3, 100751.	3.3	1
445	Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits. <i>Vaccine: X</i> , 2022, 12, 100222.	0.9	2
446	Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
449	Cryo-EM structures of prefusion SIV envelope trimer. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 1080-1091.	3.6	7
451	Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	0
454	Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates. <i>Nature Communications</i> , 2023, 14, .	5.8	14
455	Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies. <i>Journal of Virology</i> , 2023, 97, .	1.5	4
456	Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on <i>Plasmodium falciparum</i> Pfs230. <i>Immunity</i> , 2023, 56, 420-432.e7.	6.6	5
457	Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles. <i>Journal of Virology</i> , 2023, 97, .	1.5	10

#	ARTICLE	IF	CITATIONS
459	A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design. Journal of Experimental Medicine, 2023, 220, .	4.2	4